Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Natalie Meeks

Dermatology Watkinsville, GA Medical Doctor

NPI 1538554522 CMS profile 4224885

1180 Resurgence Dr Ste 100, Watkinsville, GA 30677

Open in the dashboard

General payments

$4,780

270 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Natalie Meeks of Watkinsville, GA is reported in the CMS Open Payments database as having received $4,780 across 270 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,234 66
2024 General $1,280 62
2023 General $453 20
2022 General $289 16
2021 General $803 64
2020 General $401 29
2019 General $320 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Natalie Meeks
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Natalie Meeks were reported at $1,234. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Natalie Meeks Dermatology median Middle half National median
2019 $320 $454 $129–$1,240 $163
2020 $401 $235 $81–$756 $114
2021 $803 $377 $108–$1,108 $132
2022 $289 $514 $143–$1,391 $149
2023 $453 $607 $159–$1,674 $160
2024 $1,280 $751 $204–$1,903 $164
2025 $1,234 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $807 39 payments
  2. AbbVie, Inc. $661 30 payments
  3. Genzyme Corporation $605 31 payments
  4. Galderma Laboratories, L.P. $420 29 payments
  5. Janssen Biotech, Inc. $343 19 payments
  6. Sun Pharmaceutical Industries Inc. $340 18 payments
  7. VYNE Pharmaceuticals Inc. $318 27 payments
  8. UCB, Inc. $214 9 payments
  9. LEO Pharma Inc. $171 17 payments
  10. Lilly USA, LLC $133 8 payments
  11. Other $768 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,610 268 payments
  2. Education $170 2 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $794 41 payments
  2. DUPIXENT Inflammation And Immunology $463 24 payments
  3. TREMFYA $261 8 payments
  4. DUPIXENT Immunology And Inflammation $253 10 payments
  5. ORACEA $226 15 payments
  6. Bimzelx $214 9 payments
  7. RINVOQ $212 7 payments
  8. SKYRIZI Immunology $212 12 payments
  9. ZILXI $183 14 payments
  10. SKYRIZI Immunology $182 8 payments
  11. Other $2,424 184 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,933

Median for Dermatology: 534

Drug cost

$950,832

Median for Dermatology: $67,151

Branded share of claims

14%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 98 $399,626
Rinvoq Upadacitinib Brand 37 $244,229
Taltz Autoinjector Ixekizumab Brand 18 $150,894
Adbry Tralokinumab-Ldrm Brand 17 $62,699
Dupixent Syringe Dupilumab Brand 12 $44,905
Clobetasol Propionate Generic 274 $11,403
Doxycycline Ir-Dr Doxycycline Monohydrate Brand 12 $7,898
Ketoconazole Generic 258 $4,564
Triamcinolone Acetonide Generic 349 $4,423
Fluorouracil Generic 60 $4,102

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$209,157

Of which drugs: $66

Medicare patients

1,330

Average age 75

Services billed

6,025

783 women, 547 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 47%
Ischemic heart disease 27%
Diabetes 22%
Chronic kidney disease 21%
Depression 19%
Atrial fibrillation 17%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 25 84 $66

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $363
  • Regeneron Healthcare Solutions, Inc. $232
$596 110 —
Bimzelx
  • UCB, Inc. $168
$168 — —
SKYRIZI
  • AbbVie, Inc. $123
$123 — —
Winlevi
  • Sun Pharmaceutical Industries Inc. $86
$86 — —
OPZELURA
  • Incyte Corporation $54
$54 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

270 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record